In re Quality Systems, Inc. Securities Litigation

60 F. Supp. 3d 1095, 2014 U.S. Dist. LEXIS 151359, 2014 WL 5358427
CourtDistrict Court, C.D. California
DecidedOctober 20, 2014
DocketCase No. SACV 13-01818-CJC(JPRx)
StatusPublished
Cited by1 cases

This text of 60 F. Supp. 3d 1095 (In re Quality Systems, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Quality Systems, Inc. Securities Litigation, 60 F. Supp. 3d 1095, 2014 U.S. Dist. LEXIS 151359, 2014 WL 5358427 (C.D. Cal. 2014).

Opinion

ORDER GRANTING DEFENDANTS’ MOTION TO DISMISS WITH PREJUDICE

CORMAC J. CARNEY, District Judge.

I. INTRODUCTION

This is a shareholder securities class action brought against Quality Systems, Inc. (“QSI”) and its high-ranking directors and officers, Sheldon Razin, Steven Plo-chocki, and Paul Holt (collectively, “Defendants”). The claims are asserted on behalf of all persons or entities who, during May 26, 2011 through July 25, 2012 (the “Class Period”), purchased or otherwise acquired the common stock of QSI (collectively, “Plaintiffs”). The Amended Complaint alleges violations of sections 10(b) and 20(a) [1098]*1098of the Securities Exchange Act of 1934 (“SEA”), 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b-5, in connection with Defendants’ purportedly false and misleading statements regarding revenue forecasts, sales pipeline figures, and greenfield sales projections. (Dkt. No. 26 Amended Compl. [“AC”].) Before the Court is Defendants’ motion to dismiss the Amended Complaint. (Dkt. No. 29 [“Defs.’ Mot.”].) Defendants argue that the Amended Complaint fails to meet the heightened pleading requirements of Federal Rule of Civil Procedure 9(b) and the Private Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. § 78u-4(b). For the following reasons, Defendants’ motion is GRANTED WITH PREJUDICE.

II. BACKGROUND

QSI is a publicly-traded company that develops and markets practice management and electronic health records (“EHR”) software to medical and dental care providers, including scheduling and billing related software. (AC ¶ 23.) Defendant Ploehocki served as the Chief Executive Officer and a member of the Board during the Class Period; he has also been serving as President since January '25, 2012. (AC ¶ 24.) Defendant Holt served as the Chief Financial Officer during the Class Period. (AC ¶ 25.) Defendant Ra-zin is the founder of QSI and served as the Chairman of the Board during the Class Period. (AC ¶ 26.) The Amended Complaint alleges that, as high-ranking officers and directors, Defendants Ploehocki, Holt, and Razin (the “Individual Defendants”) had direct involvement and control in the day-to-day operations of QSI and had access to “real-time” data about QSI’s business and sales. (AC ¶ 2, 27.)

In 2009, Congress passed the American Recovery and Reinvestment Act (“ARRA”), which provided $60 billion in government funds to incentivize healthcare providers to transition from paper to electronically based practices.1 (AC ¶ 30.) QSI referred to the ARRA as the “number one market driver” in the healthcare information technology industry. (AC ¶ 31.) QSI’s business is heavily dependent on its ability to book new systems sales, which in turn expands its installed base to earn maintenance revenue. (AC ¶ 34.) In light of the ARRA, QSI particularly relied on “greenfield” sales — sales made to customers who previously had no EHR system in place at ■ all. (AC ¶ 38.) The Amended Complaint alleges that, in connection with its favorable projections, QSI frequently cited the high potential for sales in the greenfield market. (AC ¶¶ 38-39.) In addition to greenfield sales, QSI tracked its sales pipeline, which represents the value of all deals that QSI believes it will close within four to eight months.2 (AC ¶ 41.)

Plaintiffs contend that, during the Class Period,. Defendants misrepresented the strength of QSI’s sales figures, sales prospects, greenfield sales, and pipeline figures, and issued highly favorable earnings per share (EPS) guidance for fiscal years 2012 (“FY2012”) and 2013 (“FY2013”).3 [1099]*1099(AC ¶ 44.) Plaintiffs point to approximately thirty allegedly fraudulent statements made during the Class Period at various conferences and earnings calls and in written publications, including a shareholder letter. For example, at the Goldman Sachs Global Healthcare Conference on June 9, 2011, Defendant Holt, in response to a question about the greenfield market, stated, “it’s greenfield for the most part ... and I think it’s going to be that way for a while.” (AC ¶ 60.) In regards to QSI’s pipeline, Scott Decker, President of QSI’s NextGen division, stated at the October 27, 2011 earnings call, “[I]f you look out 12 — 12 months and further, it’s unprecedented with the amount' of demand we see coming for our clients for rollout levels to the extent they never talked to us about the past, so it is flat but I wouldn’t read much into that.” (AC ¶ 66.) The Amended Complaint contends that these and similar statements were false and misleading because QSI had already begun to experience a slowdown in its greenfield sales starting in April 2011 and a decline in the sales pipeline beginning in the fourth quarter of FY2012.4 (AC ¶ 63, 72, 81,104.)

Plaintiffs further allege that QSI issued fraudulent and misleading EPS guidance for FY2012 and FY2013. In late October 2011, Defendant Plochocki announced a projected revenue growth range of 21% to 24% and an EPS growth of 29% to 33% for FY2012. (AC ¶ 64.) These EPS projections were reaffirmed in January 2012. (AC ¶¶ 73, 75.) On May 17, 2012, QSI announced its results for FY2012 — QSI had met its revenue growth projections at 22%, but “due to delays in closing several fourth-quarter opportunities, as well as recognition of revenue related to a large customer implementation,” EPS growth was only 21%. (AC ¶ 93; Dkt. No. 29-1 Declaration of Katherine A. Rykken ISO Defendants’ Motion to Dismiss [“Rykken Decl. 1”], Exh. 13.)5 Looking ahead, QSI projected a 20% to 24% revenue growth and a 20% to 25% EPS growth for FY2013. (AC ¶ 93.) The FY2013 projections were re-stated in late June 2012 and early July 2012 in connection with proxy materials for a pending proxy contest. (AC ¶¶ 107-108.) On July 26, 2012, QSI issued a press release declining to affirm the FY2013 guidance, given that record revenues for the first quarter [1100]*1100had come in at just 18% and there was a decline in EPS and net income from the previous year’s quarter. (AC ¶ 110; Rykken Decl. 1, Exh. 24 [“July 26 Form 8-K”] at 621.) In the same press release, Defendant Plochocki explained that “overall results were impacted by lower than expected revenue from large, higher margin software system sales.” (July 26 Form 8-K at 621.)

Plaintiffs generally allege that QSI’s statements were fraudulent because they were issued contemporaneously while QSI’s new bookings and sales pipeline were declining. (AC ¶ 46, 48-56.) The Amended Complaint alleges that each of the fraudulent statements was material to investors, pointing to the positive reviews and recommendations to purchase QSI stock by analysts that followed each of QSI’s public statements. (AC ¶¶ 62, 78, 99, 102.) The Amended Complaint also alleges that the Individual Defendants possessed the requisite scienter because they were aware of QSI’s flagging financial performance as of late 2011. In support of this allegation, Plaintiffs point to the Individual Defendants’ involvement with the core operations of QSI and their access to real-time data about the sales cycle.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bodri v. GoPro, Inc.
252 F. Supp. 3d 912 (N.D. California, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
60 F. Supp. 3d 1095, 2014 U.S. Dist. LEXIS 151359, 2014 WL 5358427, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-quality-systems-inc-securities-litigation-cacd-2014.